StockNews.com Upgrades Pediatrix Medical Group (NYSE:MD) to Buy

StockNews.com upgraded shares of Pediatrix Medical Group (NYSE:MD) from a hold rating to a buy rating in a report released on Thursday morning.

Several other brokerages have also weighed in on MD. UBS Group increased their target price on Pediatrix Medical Group from $10.50 to $16.50 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Macquarie started coverage on Pediatrix Medical Group in a report on Monday, December 16th. They issued an “outperform” rating and a $18.00 price objective on the stock. Deutsche Bank Aktiengesellschaft lifted their price objective on Pediatrix Medical Group from $9.00 to $15.00 and gave the company a “hold” rating in a research note on Monday, November 4th. Truist Financial dropped their target price on shares of Pediatrix Medical Group from $16.00 to $15.00 and set a “hold” rating for the company in a research report on Monday, January 6th. Finally, Jefferies Financial Group lifted their price target on shares of Pediatrix Medical Group from $14.00 to $18.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $16.25.

Pediatrix Medical Group Stock Down 2.1 %

MD opened at $12.46 on Thursday. Pediatrix Medical Group has a 12 month low of $6.62 and a 12 month high of $16.41. The business has a 50-day moving average of $14.30 and a two-hundred day moving average of $11.60. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.42 and a quick ratio of 1.42. The stock has a market capitalization of $1.07 billion, a price-to-earnings ratio of -4.07, a price-to-earnings-growth ratio of 2.00 and a beta of 1.58.

Pediatrix Medical Group (NYSE:MD) last released its earnings results on Friday, November 1st. The company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.07. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The firm had revenue of $511.20 million during the quarter, compared to the consensus estimate of $498.87 million. During the same period in the previous year, the firm earned $0.29 earnings per share. Pediatrix Medical Group’s revenue was up .9% compared to the same quarter last year. On average, research analysts expect that Pediatrix Medical Group will post 1.26 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Mark S. Ordan sold 27,600 shares of Pediatrix Medical Group stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $15.35, for a total transaction of $423,660.00. Following the sale, the director now directly owns 138,683 shares of the company’s stock, valued at approximately $2,128,784.05. The trade was a 16.60 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Mary Ann E. Moore sold 8,108 shares of the stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $16.00, for a total value of $129,728.00. Following the completion of the transaction, the executive vice president now directly owns 135,810 shares of the company’s stock, valued at $2,172,960. This represents a 5.63 % decrease in their position. The disclosure for this sale can be found here. 2.00% of the stock is owned by company insiders.

Institutional Trading of Pediatrix Medical Group

A number of hedge funds have recently made changes to their positions in the stock. Quest Partners LLC boosted its stake in Pediatrix Medical Group by 25.6% during the 3rd quarter. Quest Partners LLC now owns 3,054 shares of the company’s stock valued at $35,000 after acquiring an additional 622 shares during the last quarter. Quarry LP lifted its position in shares of Pediatrix Medical Group by 54.1% during the third quarter. Quarry LP now owns 4,735 shares of the company’s stock worth $55,000 after purchasing an additional 1,662 shares during the last quarter. CWM LLC grew its stake in Pediatrix Medical Group by 134.0% in the third quarter. CWM LLC now owns 6,427 shares of the company’s stock worth $74,000 after purchasing an additional 3,681 shares in the last quarter. Canada Pension Plan Investment Board bought a new stake in Pediatrix Medical Group in the second quarter valued at about $72,000. Finally, FMR LLC increased its holdings in Pediatrix Medical Group by 220.6% in the third quarter. FMR LLC now owns 9,841 shares of the company’s stock valued at $114,000 after buying an additional 6,771 shares during the last quarter. Institutional investors and hedge funds own 97.71% of the company’s stock.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.